Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)

University of Toronto

$120,000.00

A Target Trial Emulation Study on the Comparative Effectiveness of Sodium Glucose Transporter Inhibitors in Improving Cardiovascular and Renal Outcomes among Patients with Chronic Kidney Disease

EF 2025-26

Résumé
People with chronic kidney disease are at high risk of heart and kidney problems. Some medications classified as sodium glucose transporter-2 inhibitors (SGLT2i) - canagliflozin, dapagliflozin, and empagliflozin - are approved to help protect heart and kidney function. While all three are effective, it is not yet clear which one works best, particularly in older adults with chronic kidney disease. The best way to answer this question is to conduct large clinical trials. Clinical trials randomly assign participants to treatments, which minimizes bias from other factors that can influence treatment decision and health outcomes. However, trials are costly and often difficult to run, especially when funding involves multiple pharmaceutical companies. As an alternative, researchers can use large real-world healthcare databases to conduct observational studies. Past studies of this kind have been criticized for using poor designs, which can lead to biased results. A newer method, known as target trial emulation, help researchers design observational studies that more closely mimic clinical trials and reduce bias. In this study, we will use health data from more than 500,000 Ontarians aged 66 years or older with chronic kidney disease. These patients will be identified through the administrative healthcare databases from ICES (formerly the Institute of Clinical Evaluative Services) with linkage to population data, the CorHealth Cardiac registry, and billions of laboratory data. Using the target trial emulation method on these large, linked healthcare databases, we will compare the three SGLT2 inhibitors and determine which one is most effective in protecting heart and kidney function. Our findings will have significant clinical impacts by guiding treatment choices in older adults with chronic kidney disease and improving health outcomes. Methodologically, this study will contribute to advancing and appropriately implementing this novel research method.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
559714
Name
Islam Sunjidatul
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
DT2 (Health services and population health research) CGRS Doctoral
Projecttitle
A Target Trial Emulation Study on the Comparative Effectiveness of Sodium Glucose Transporter Inhibitors in Improving Cardiovascular and Renal Outcomes among Patients with Chronic Kidney Disease
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Cardiovascular Disease; Chronic Kidney Disease; Primary Prevention; Treatment Effectiveness
Abstract
People with chronic kidney disease are at high risk of heart and kidney problems. Some medications classified as sodium glucose transporter-2 inhibitors (SGLT2i) - canagliflozin, dapagliflozin, and empagliflozin - are approved to help protect heart and kidney function. While all three are effective, it is not yet clear which one works best, particularly in older adults with chronic kidney disease. The best way to answer this question is to conduct large clinical trials. Clinical trials randomly assign participants to treatments, which minimizes bias from other factors that can influence treatment decision and health outcomes. However, trials are costly and often difficult to run, especially when funding involves multiple pharmaceutical companies. As an alternative, researchers can use large real-world healthcare databases to conduct observational studies. Past studies of this kind have been criticized for using poor designs, which can lead to biased results. A newer method, known as target trial emulation, help researchers design observational studies that more closely mimic clinical trials and reduce bias. In this study, we will use health data from more than 500,000 Ontarians aged 66 years or older with chronic kidney disease. These patients will be identified through the administrative healthcare databases from ICES (formerly the Institute of Clinical Evaluative Services) with linkage to population data, the CorHealth Cardiac registry, and billions of laboratory data. Using the target trial emulation method on these large, linked healthcare databases, we will compare the three SGLT2 inhibitors and determine which one is most effective in protecting heart and kidney function. Our findings will have significant clinical impacts by guiding treatment choices in older adults with chronic kidney disease and improving health outcomes. Methodologically, this study will contribute to advancing and appropriately implementing this novel research method.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Islam, Sunjidatul
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~